Morphic Therapeutic, Inc.
Clinical trials sponsored by Morphic Therapeutic, Inc., explained in plain language.
Biotech developing oral integrin therapies, acquired by Eli Lilly.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New oral drug shows promise for ulcerative colitis in early trial
Disease control CompletedThis study tested an experimental pill called MORF-057 in 39 adults with moderate to severe ulcerative colitis. The drug aims to reduce gut inflammation by blocking a specific protein. Researchers measured changes in colon tissue health and symptom scores after 12 weeks of treatm…
Phase 2 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Healthy volunteers test new drug MORF-440 for safety
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug, MORF-440, in 80 healthy adults. Participants received either a single dose or multiple doses to see how the body handles it and if any side effects occur. The goal was not to treat a disease but to gather important safety in…
Phase 1 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC